Scarica l'app Stockscreener
348.85
1.43%
-5.07
Pre-mercato:
348.85
Precedente Chiudi:
$353.92
Aprire:
$350.69
Volume 24 ore:
247.16K
Relative Volume:
0.84
Capitalizzazione di mercato:
$38.60B
Reddito:
$4.98B
Utile/perdita netta:
$69.60M
Rapporto P/E:
671.12
EPS:
0.5198
Flusso di cassa netto:
$525.67M
1 W Prestazione:
+1.12%
1M Prestazione:
+3.24%
6M Prestazione:
+21.05%
1 anno Prestazione:
+56.09%
Intervallo 1D:
$345.47
$358.00
Intervallo di 1 settimana:
$340.00
$358.00
Portata 52W:
$196.45
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Nome
Beone Medicines Ltd Adr
Settore
Industria
Telefono
41-616851900
Indirizzo
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, REGN, ARGX, ALNY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
348.85 | 39.16B | 4.98B | 69.60M | 525.67M | 0.5198 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.87 | 121.26B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.28 | 83.04B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
828.24 | 50.22B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.00 | 43.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-24 | Iniziato | Truist | Buy |
| 2025-09-18 | Iniziato | Barclays | Overweight |
| 2025-04-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-03-03 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-12-03 | Ripresa | Morgan Stanley | Overweight |
| 2024-09-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-02-06 | Ripresa | JP Morgan | Overweight |
| 2023-09-12 | Iniziato | Macquarie | Outperform |
| 2023-08-17 | Iniziato | Jefferies | Buy |
| 2023-07-17 | Iniziato | Citigroup | Buy |
| 2023-06-30 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Iniziato | Daiwa Securities | Buy |
| 2022-10-13 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-10-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Ripresa | JP Morgan | Overweight |
| 2022-03-17 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Iniziato | Deutsche Bank | Buy |
| 2021-10-12 | Iniziato | Bernstein | Outperform |
| 2021-10-06 | Aggiornamento | CLSA | Underperform → Buy |
| 2021-03-08 | Iniziato | China Renaissance | Buy |
| 2021-03-01 | Downgrade | CLSA | Outperform → Underperform |
| 2020-11-09 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Downgrade | Maxim Group | Buy → Hold |
| 2020-11-06 | Downgrade | Piper Sandler | Neutral → Underweight |
Mostra tutto
Beone Medicines Ltd Adr Borsa (ONC) Ultime notizie
Candriam S.C.A. Sells 67,718 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Chan Henry Lee Sells 1,660 Shares of BeOne Medicines (NASDAQ:ONC) Stock - MarketBeat
BeOne Medicines Trial Wins And Sonrotoclax Clearance Meet Valuation Discount - Sahm
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Sees Significant Decline in Short Interest - MarketBeat
3 Stocks to Buy in February - Finviz
Wall Street Bullish on BeOne Medicines AG (ONC) amid Robust Pipeline Development - Finviz
Mirae Asset Global Investments Co. Ltd. Acquires 38,992 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Citizens Highlights BeOne Medicines' (ONC) $3.8B Revenue Potential for 2025 - Finviz
BeOne Medicines Collaboration Extends Safety Modeling As Shares Trade Below Targets - Sahm
FDA Accepts Summit's Lung Cancer Drug Application, Review Underway - Benzinga
Assessing BeOne Medicines (ONC) Valuation After Expanded InSysBio Collaboration On Clinical Trial Modeling - Sahm
Did BeOne’s New Uptrend And Upgraded Earnings Outlook Just Shift Its (ONC) Investment Narrative? - simplywall.st
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
EMCOR Group, Inc. (NYSE:EME) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Financial Review: Atossa Genetics (NASDAQ:ATOS) versus ADM Tronics Unlimited (OTCMKTS:ADMT) - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap DownShould You Sell? - MarketBeat
BeOne Medicines Earnings Momentum Spurs Valuation Debate And Analyst Optimism - Sahm
Five Below Upgraded, Spotify Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BEONE MEDICINES LTD-ADR (NASDAQ:ONC) Passes Minervini Trend Template and Strong Growth Scan - Chartmill
CICC Predicts HSI to Add ZIJIN GOLD INTL/ BEONE MEDICINES/ PICC P&C/ AKESO as New Constituents; STANCHART May Replace HANG SENG BANK - AASTOCKS.com
Assessing BeOne Medicines (ONC) Valuation After A Year Of Strong Shareholder Returns - Sahm
HERIZON-GEA-01 Phase 3 Zanidatamab Combo Data Might Change The Case For Investing In BeOne Medicines (ONC) - Sahm
Chan Henry Lee Sells 664 Shares of BeOne Medicines (NASDAQ:ONC) Stock - Defense World
JGP Global Gestao de Recursos Ltda. Decreases Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Fingerlakes Wealth Management Inc. Has $6.96 Million Holdings in Schwab U.S. Large-Cap Growth ETF $SCHG - Defense World
BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 664 Shares - MarketBeat
Snowline Gold (CVE:SGD) Shares Up 3% – Here’s What Happened - Defense World
Is the Options Market Predicting a Spike in BeOne Medicines Stock? - Yahoo Finance
BrightSpire Capital (NYSE:BRSP) Shares Gap Down – Here’s What Happened - Defense World
BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Voya Investment Management LLC Raises Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
John Oyler Sells 75,631 Shares of BeOne Medicines (NASDAQ:ONC) Stock - Defense World
BeOne Medicines appoints Dr. Lai Wang as president and global head of R&D - Investing.com
BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 24,369 Shares - MarketBeat
BeOne Medicines (NASDAQ:ONC) Shares Gap Down After Insider Selling - Defense World
BeOne Medicines (NASDAQ:ONC) Shares Gap Down Following Insider Selling - MarketBeat
Ford Upgraded, Amazon Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
LMR Partners LLP Acquires New Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
China Universal Asset Management Co. Ltd. Makes New Investment in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) SVP Sells $107,900.00 in Stock - MarketBeat
35,910 Shares in BeOne Medicines Ltd. – Sponsored ADR $ONC Purchased by Axa S.A. - Defense World
Bellevue Group AG Makes New $9.37 Million Investment in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
35,910 Shares in BeOne Medicines Ltd.Sponsored ADR $ONC Purchased by Axa S.A. - MarketBeat
Lee Chan Henry, SVP at BeOne Medicines, sells shares worth $213,568 - Investing.com
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases Shares of 9,377 BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
12,338 Shares in BeOne Medicines Ltd. – Sponsored ADR $ONC Purchased by American Century Companies Inc. - Defense World
8,037 Shares in BeOne Medicines Ltd.Sponsored ADR $ONC Acquired by Guggenheim Capital LLC - MarketBeat
First Trust Advisors LP Makes New Investment in BeOne Medicines Ltd. – Sponsored ADR $ONC - Defense World
First Trust Advisors LP Makes New Investment in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
12,338 Shares in BeOne Medicines Ltd.Sponsored ADR $ONC Purchased by American Century Companies Inc. - MarketBeat
Temasek Holdings Private Ltd Acquires New Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Beone Medicines Ltd Adr Azioni (ONC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.49%
3.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):